December 6, 2023

Dermavant Announces Positive Results from Phase 4 ...

Read More

October 20, 2023

Dermavant Presents Positive Results from Phase 4 O ...

Read More

October 16, 2023

Dermavant to Present New Positive Data from Phase ...

Read More

October 13, 2023

Dermavant Champions a Culture that Earns Three Bes ...

Read More

October 12, 2023

Dermavant Announces New Positive Pruritus Data for ...

Read More

October 6, 2023

Dermavant to Present Data from ADORING 1 and 2 Piv ...

Read More

October 5, 2023

Dermavant Appoints John Darden as New Head of Mark ...

Read More

May 16, 2023

Dermavant Reports Positive Topline Results from AD ...

Read More

March 15, 2023

Dermavant Reports Positive Topline Results from AD ...

Read More

March 10, 2023

Dermavant to Present Data from Multiple Studies of ...

Read More

February 13, 2023

Dermavant Completes Enrollment of Two Phase 3 Clin ...

Read More

January 12, 2023

Dermavant to Present Data from Multiple Studies of ...

Read More

October 13, 2022

Dermavant to Present Data from Multiple Clinical T ...

Read More

March 25, 2022

Dermavant Showcases New Long-Term Durability and T ...

Read More

March 11, 2022

Dermavant to Present New Data from the Phase 3 PSO ...

Read More

March 8, 2022

Dermavant Appoints Nancy Beesley to its Board of D ...

Read More

January 15, 2022

Dermavant Presents New Patient Satisfaction Data f ...

Read More

January 7, 2022

Dermavant to Present New Data from Phase 3 PSOARIN ...

Read More

December 9, 2021

Dermavant Announces Publication of PSOARING 1  ...

Read More

December 9, 2021

The New England Journal of Medicine: Phase 3 Trial ...

Read More